Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05972577 · ClinicalTrials.gov registry record · NA

Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study

A NA study of Acute Myeloid Leukemia and Chronic Lymphocytic Leukemia, sponsored by Ohio State University Comprehensive Cancer Center.

Active
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT05972577: Active NA study of Acute Myeloid Leukemia and Chronic Lymphocytic Leukemia, sponsored by Ohio State University Comprehensive Cancer Center.

NCT05972577 is a NA study of Acute Myeloid Leukemia and Chronic Lymphocytic Leukemia that is active but no longer recruiting, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 30 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05972577, a NA study of Acute Myeloid Leukemia and Chronic Lymphocytic Leukemia, is active but no longer recruiting, sponsored by Ohio State University Comprehensive Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This clinical trial tests whether a geriatric optimization plan (GO!) works to improve survival in patients over 60 with a hematologic malignancy or bone marrow failure syndrome eligible for allogeneic hematopoietic cell transplant. GO! focuses on creating a tailored and specific plan for each patient to make changes in their daily lives. These may include changes to their diet, sleep, activity, medicines, or even referrals to other providers depending on the patient's needs. Studying survival and quality of life in patients over 60 receiving an allogeneic hematopoietic cell transplant may help identify the effects of treatment.

Primary Outcome

Wilcoxon signed rank test or McNemar test will be used to assess the change over time in geriatric assessment tools.

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Questionnaire Administration
  • OTHER Medical Device Usage and Evaluation
  • OTHER Health Promotion and Education

Study Locations (1)

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2021-06-02
Est. Completion 2025-12-31
Phase NA

What the registry record for NCT05972577 still lists

NCT05972577 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (74% lower).

The record links to 10 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.

NCT05972577 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT05972577 about?

NCT05972577 is a clinical study titled "Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study". This clinical trial tests whether a geriatric optimization plan (GO!) works to improve survival in patients over 60 with a hematologic malignancy or bone marrow failure syndrome eligible for allogeneic hematopoietic cell transplant. GO! focuses on creating a tailored and specific plan for each patie...

What is the current status of trial NCT05972577?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2021-06-02. Estimated completion is 2025-12-31.

What conditions does trial NCT05972577 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Hematopoietic and Lymphoid Cell Neoplasm.

What interventions are being tested in trial NCT05972577?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Medical Device Usage and Evaluation (OTHER), Health Promotion and Education (OTHER).

Who is sponsoring clinical trial NCT05972577?

This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05972577 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05972577's enrollment target sits among peer trials

30 204th of 306 higher than 97 of 306 other Acute Myeloid Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05972577, the US trial registry maintained by the National Library of Medicine. NCT05972577 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.